Status:
COMPLETED
Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Vascular Dementia
Eligibility:
All Genders
50-85 years
Phase:
PHASE3
Brief Summary
The goal of this research study is to evaluate the effectiveness, tolerability and safety of rivastigmine capsules in males and females between the ages of 50 and 85 years old with probable vascular d...
Eligibility Criteria
Inclusion
- Between the ages of 50 and 85 years old
- Have contact with a responsible caregiver 3 or more days per week
- Be male or a female who is surgically sterilized or one year post menopausal
Exclusion
- Current diagnosis of severe or unstable cardiovascular or other diseases
- Current diagnosis of active, uncontrolled seizure disorder, Parkinson's disease or Alzheimer's disease
Key Trial Info
Start Date :
August 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2005
Estimated Enrollment :
708 Patients enrolled
Trial Details
Trial ID
NCT00099216
Start Date
August 1 2001
End Date
November 1 2005
Last Update
November 17 2011
Active Locations (63)
Enter a location and click search to find clinical trials sorted by distance.
1
Irvine, California, United States, 92618
2
San Francisco, California, United States, 94109
3
Boynton Beach, Florida, United States, 33426
4
Miami Beach, Florida, United States, 33140